NCT07348055 A Study of GR1803 in Systemic Lupus Erythematosus
| NCT ID | NCT07348055 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Condition | Systemic Lupus Erthematosus |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2027-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 44 participants in total. It began in 2026-02-02 with a primary completion date of 2027-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Eligibility Criteria
Inclusion Criteria: * comfirmed diagnosis of systemic lupus erythematosus * SLEDAI-2K≥6分 * written informed consent and ability to comply with protocol requirements * have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months Exclusion Criteria: * with unstable acute and chronic diseases * active infection * history of malignant tumor within 5 years
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07348055 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Systemic Lupus Erthematosus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07348055 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07348055 currently recruiting?
Yes, NCT07348055 is actively recruiting participants. Contact the research team at nianhanli@genrixbio.com for enrollment information.
Where is the NCT07348055 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07348055 clinical trial?
NCT07348055 is sponsored by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. The trial plans to enroll 44 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.